Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Arthritis
- Proteins
- Therapeutic
- ribonucleic acid
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 283821
License Grant
In the Territory, the Swiss Licensor grants to the Licensee of the Cayman Islands an exclusive, including with regard to Licensor and its Affiliates, but excluding any non-exclusive license granted to Another Party by operation of Another Development and License Agreement license, with the right to grant sublicenses to Sublicensees, under Licensor Intellectual Property and Know-How; and an exclusive, including with regard to Licensor and its Affiliates sublicense, with the right to grant sub-sublicenses to Sub-sublicensees, under Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Compound and the Licensed Product in the Field in the Territory.
For the Option Right of the Licensee to the Optional Territory Licensor grants a non-exclusive option right to obtain an exclusive license, with the right to grant sublicenses to Sublicensees, under Licensor Intellectual Property and Know-How; and a non-exclusive option right to obtain an exclusive sublicense, with the right to grant sub-sublicenses to Sub-sublicensees, under Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Product in the Field in the mutually agreed upon countries in the Optional Territory,
License Property
Licensor has an exclusive license to certain Sublicensed Intellectual Property and certain Intellectual Property and Know-How with respect to the Licensed Compound and the Licensed Product.
Licensed Compound means FE301, i.e., SGP130Fc fusion protein, an interleukin-6 inhibitor.
The patents are for FE301 composition; FE301 dosing; Fusion proteins comprising two soluble gp130 molecules; Optimized nucleotide sequences encoding sgp130; and Improved sgp130Fc dimers.
Optimized nucleotide sequences encoding sgp130 Patent No. 8,206,948
Olamkicept is a new recombinant protein inhibitor of the interleukin-6 pathway. Interleukin-6 is associated with numerous inflammatory conditions such as inflammatory bowel diseases (IBD) and rheumatoid arthritis.
Field of Use
Field means any indication for medicinal use in humans, including rheumatoid arthritis.
IPSCIO Record ID: 237243
License Grant
Licensor grants to the United Kingdom Licensee a non-exclusive license, without the right to sublicense, in the territory in the field of use and under the Patent Rights to research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, and export Licensed Products, and research, develop, use, and practice Licensed Processes only for the purposes of manufacturing or having manufactured the Licensed Products.
Licensor grants a non-exclusive license, without the right to sublicense, in the Territory to conduct preclinical research and/or pre-Phase II clinical trials ( or the equivalent of pre-Phase II clinical trials in the U.S. or other countries) involving the use of Licensed Products in indications outside of the Field of Use.
License Property
The Licensed Product means the first three (3) short consensus repeat protein domains of human complement receptor type 1 (CRI), derivatized to include a myristoyl peptide, having Licensees designation -070 or any successor product of such -070 which is an optimization or derivative of -070, the development, manufacture, use, sale, offer for sale, importation or distribution.
Field of Use
The field of use means the treatment of rheumatoid arthritis.
IPSCIO Record ID: 245716
License Grant
The Swiss Licensor grants to the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, for Licensee and its Affiliates to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
The nti-IL6R antibodies marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. The Licensee intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases.
Field of Use
Field means any and all uses including all therapeutic uses. Licensed IP includes the nti-IL6R antibodies for a range of inflammatory conditions including rheumatoid arthritis.
Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (“BMSâ€), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.
IPSCIO Record ID: 286023
License Grant
The Licensor of England grants a right and license to develop, make, have made, use, offer for sale, sell, have sold, import and export Licensed Products for use in the Field in the Territory.
The license s exclusive or non-exclusive on a patent by patent basis.
License Property
Licensor has a product, known as Cxx-870, which contains a recombinant humanized pegylated Fab’ antibody fragment which binds to TNF alpha, or Tumor Necrosis Factor? alpha.
Licensed Product means any product that contains or comprises an Antibody, or any chemically modified Antibody, which recognizes TNF alpha. For the avoidance of doubt, Licensed Product shall not include non-Antibody inhibitors of TNF alpha.
The patents are titled Multichain Polypeptides or Proteins and Processes for their Production;
Recombinant Antibody; Humanized Antibodies; Protein Expression System; Process for obtaining Antibodies; Monovalent Antibody Fragments; and, Biological Products.
Field of Use
Field means the prevention, treatment, diagnosis or control of all diseases or conditions in humans or animals; provided, however, that with respect to CDP-571, the Field shall not include the prevention, treatment, diagnosis or control of any diseases or conditions other than rheumatoid arthritis.
IBD Indication means the prevention, treatment or control of Crohn’s Disease and/or ulcerative colitis in humans and/or animals.
RA Indication means the prevention, treatment or control of rheumatoid arthritis in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
